SEC Form 4 · accession 0001404955-26-000006

Stoke Therapeutics, Inc. · STOK

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Seth Loring Harrison

Director

Period of report

Jul 16, 2026

Accepted (ET)

Jul 17, 2026 · 4:37 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001623526

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F2	$28.80	Jul 16, 2026	G	29,555	D	—	Sep 9, 2029	Common Stock	29,555	0	D
Stock Option (Right to Buy)^F3,F2	$28.80	Jul 16, 2026	G	29,555	A	—	Sep 9, 2029	Common Stock	29,555	29,555	I
Stock Option (Right to Buy)^F4	$26.53	Jul 16, 2026	G	14,777	D	—	Jun 2, 2030	Common Stock	14,777	0	D
Stock Option (Right to Buy)^F3,F4	$26.53	Jul 16, 2026	G	14,777	A	—	Jun 2, 2030	Common Stock	14,777	14,777	I
Stock Option (Right to Buy)^F5	$40.37	Jul 16, 2026	G	11,650	D	—	Jun 7, 2031	Common Stock	11,650	0	D
Stock Option (Right to Buy)^F3,F5	$40.37	Jul 16, 2026	G	11,650	A	—	Jun 7, 2031	Common Stock	11,650	11,650	I
Stock Option (Right to Buy)^F6	$12.96	Jul 16, 2026	G	21,000	D	—	Jun 6, 2032	Common Stock	21,000	0	D
Stock Option (Right to Buy)^F3,F6	$12.96	Jul 16, 2026	G	21,000	A	—	Jun 6, 2032	Common Stock	21,000	21,000	I
Stock Option (Right to Buy)^F7	$12.46	Jul 16, 2026	G	19,441	D	—	Jun 12, 2033	Common Stock	19,441	0	D
Stock Option (Right to Buy)^F3,F7	$12.46	Jul 16, 2026	G	19,441	A	—	Jun 12, 2033	Common Stock	19,441	19,441	I
Stock Option (Right to Buy)^F8	$16.41	Jul 16, 2026	G	7,639	D	—	Jun 4, 2034	Common Stock	7,639	0	D
Stock Option (Right to Buy)^F3,F8	$16.41	Jul 16, 2026	G	7,639	A	—	Jun 4, 2034	Common Stock	7,639	7,639	I
Stock Option (Right to Buy)^F9	$10.90	Jul 16, 2026	G	29,747	D	—	Jun 2, 2035	Common Stock	29,747	0	D
Stock Option (Right to Buy)^F3,F9	$10.90	Jul 16, 2026	G	29,747	A	—	Jun 2, 2035	Common Stock	29,747	29,747	I
Stock Option (Right to Buy)^F10	$29.46	Jul 16, 2026	G	17,786	D	—	Jun 2, 2036	Common Stock	17,786	0	D
Stock Option (Right to Buy)^F3,F10	$29.46	Jul 16, 2026	G	17,786	A	—	Jun 2, 2036	Common Stock	17,786	17,786	I

Explanation of responses

F1The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended.
F10The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date.
F2This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022.
F3The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust.
F4This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021.
F5This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022.
F6This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023.
F7This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024.
F8This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025.
F9This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026.